MAP2K2 and myeloid sarcoma: Indeed, increased fibrin deposition, paxillin, MAPK and sustained MEK2 activation, and NADPH oxidase activity promote oxidative injury and mediate neurodegeneration and synaptic dysfunction in both MS and AD6,20,43–47.